Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Week 104 results from the SUNSHINE and SUNRISE extension trial.
Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, Reguiai Z, Villani AP, Alarcon I, Bansal A, Gasperoni F, Martin R, Paguet B, Uhlmann L, Zouater H, Ravichandran S, Alavi A. Kimball AB, et al. Among authors: alarcon i. Br J Dermatol. 2024 Nov 29:ljae469. doi: 10.1093/bjd/ljae469. Online ahead of print. Br J Dermatol. 2024. PMID: 39611771
The RICA-2 registry: design and baseline characteristics of the first 1,000 patients.
Trullàs JC, Moreno-García MC, Mittelbrunn-Alquézar V, Conde-Martel A, Soler-Rangel L, Montero-Pérez-Barquero M, Casado J, Sánchez-Marteles M, Arévalo-Lorido JC, Pérez-Silvestre J; investigadores del registro RICA-2. Trullàs JC, et al. Rev Clin Esp (Barc). 2024 Oct;224(8):522-533. doi: 10.1016/j.rceng.2024.07.008. Epub 2024 Jul 23. Rev Clin Esp (Barc). 2024. PMID: 39053884
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
NIHR Global Health Research Unit on Global Surgery; STARSurg Collaborative. NIHR Global Health Research Unit on Global Surgery, et al. Lancet Digit Health. 2024 Jul;6(7):e507-e519. doi: 10.1016/S2589-7500(24)00065-7. Lancet Digit Health. 2024. PMID: 38906616 Free article.
Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Ophthalmol Retina. 2024 Oct;8(10):962-970. doi: 10.1016/j.oret.2024.04.014. Epub 2024 Apr 18. Ophthalmol Retina. 2024. PMID: 38641007
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: alarcon i. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, Elkayam O. Eviatar T, et al. Among authors: alarcon i. J Rheumatol. 2024 Apr 1;51(4):415-422. doi: 10.3899/jrheum.2023-0357. J Rheumatol. 2024. PMID: 37914221 Free article.
104 results